Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Fibromuscular dysplasia - results of a multicentre study in Flanders.

De Groote M, Van der Niepen P, Hemelsoet D, Callewaert B, Vermassen F, Billiouw JM, De Vriese A, Donck J, De Backer T.

Vasa. 2017 May;46(3):211-218. doi: 10.1024/0301-1526/a000613. Epub 2017 Feb 3.

PMID:
28157058
2.

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.

Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.

3.

The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.

Clin J Am Soc Nephrol. 2015 May 7;10(5):791-9. doi: 10.2215/CJN.07730814. Epub 2015 Feb 20.

4.

Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study).

Deray G, Rouviere O, Bacigalupo L, Maes B, Hannedouche T, Vrtovsnik F, Rigothier C, Billiouw JM, Campioni P, Ferreiros J, Devos D, Alison D, Glowacki F, Boffa JJ, Marti-Bonmati L.

Eur Radiol. 2013 May;23(5):1250-9. doi: 10.1007/s00330-012-2705-x. Epub 2012 Dec 5.

5.

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.

EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS.

N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3.

6.

Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials.

Tielemans CL, Vlasak J, Kosa D, Billiouw JM, Verpooten GA, Mezei I, Ryba M, Peeters PC, Mat O, Jadoul MY, Polakovic V, Dhaene M, Treille S, Kuriyakose SO, Leyssen M, Houard SA, Surquin M.

Vaccine. 2011 Feb 1;29(6):1159-66. doi: 10.1016/j.vaccine.2010.12.009. Epub 2010 Dec 16.

PMID:
21167859
7.

Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend.

Van Mieghem W, Billiouw JM, Brohet C, Dupont AG, Gazagnes MD, Heller F, Krzesinski JM, Missault L, Persu A, Piérard L, Rottiers R, Vanhooren G, Vervaet P, Herman AG.

Acta Clin Belg. 2010 Mar-Apr;65(2):107-14.

8.

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group.

N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30. Erratum in: N Engl J Med. 2010 Apr 15;362(15):1450.

9.

Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.

Hutchison AJ, Barnett ME, Krause R, J, Siami GA; Lanthanum Carbonate Study Group.

Clin Nephrol. 2009 Mar;71(3):286-95.

PMID:
19281739
10.

Discovery Belux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia.

Herregods MC, Daubresse JC, Michel G, Lamotte M, Vissers E, Vandenhoven G; Discovery Belux.

Acta Cardiol. 2008 Aug;63(4):493-9.

PMID:
18795588
11.

Lessons from ONTARGET.

Berlaimont V, Billiouw JM, Brohet C, Dupont AG, Gazagnes MD, Heller F, Krzesinski JM, Missault L, Persu A, Piérard L, Rottiers R, Vanhooren G, Van Mieghem W, Vervaet P, Herman AG.

Acta Clin Belg. 2008 May-Jun;63(3):142-51. Review.

12.

The enigma of hypertensive ESRD: observations on incidence and trends in 18 European, Canadian, and Asian-Pacific populations, 1998 to 2002.

Stewart JH, McCredie MR, Williams SM; Canadian Organ Replacement Register, Fenton SS, Trpeski L; Australia and New Zealand Dialysis and Transplant Registry, McDonald SP; European Renal Association-European Dialysis and Transplant Association Registry, Jager KJ, van Dijk PC; Finnish Registry for Kidney Diseases, Finne P; Swedish Registry for Active Treatment of Uremia, Schon S; Norwegian Renal Registry, Leivestad T; Danish National Registry on Regular Dialysis and Transplantation, Løkkegaard H; Dutch-speaking Belgian Society of Nephrology, Billiouw JM; Austrian Dialysis and Transplant Registry, Kramar R; Basque Renal Patients' Registry, Magaz A; Catalan Renal Registry, Vela E; Valencian Renal Registry, Garcia-Blasco MJ; Hellenic Renal Registry, Ioannidis GA; Malaysian National Renal Registry, Lim YN.

Am J Kidney Dis. 2006 Aug;48(2):183-91.

PMID:
16860183
13.

Biochemical validation of a rat model for polycystic kidney disease: comparison of guanidino compound profile with the human condition.

Torremans A, Marescau B, Kränzlin B, Gretz N, Billiouw JM, Vanholder R, De Smet R, Bouwman K, Brouns R, De Deyn PP.

Kidney Int. 2006 Jun;69(11):2003-12.

14.

Impact of convective flow on phosphorus removal in maintenance hemodialysis patients.

Lornoy W, De Meester J, Becaus I, Billiouw JM, Van Malderen PA, Van Pottelberge M.

J Ren Nutr. 2006 Jan;16(1):47-53.

PMID:
16414441
15.

Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study.

Lins RL, Matthys KE, Billiouw JM, Dratwa M, Dupont P, Lameire NH, Peeters PC, Stolear JC, Tielemans C, Maes B, Verpooten GA, Ducobu J, Carpentier YA.

Clin Nephrol. 2004 Oct;62(4):287-94.

PMID:
15524059
16.

Re-evaluation and modification of the Stuivenberg Hospital Acute Renal Failure (SHARF) scoring system for the prognosis of acute renal failure: an independent multicentre, prospective study.

Lins RL, Elseviers MM, Daelemans R, Arnouts P, Billiouw JM, Couttenye M, Gheuens E, Rogiers P, Rutsaert R, Van der Niepen P, De Broe ME.

Nephrol Dial Transplant. 2004 Sep;19(9):2282-8. Epub 2004 Jul 20.

PMID:
15266030
17.

The low nanomolar levels of N G-monomethylarginine in serum and urine of patients with chronic renal insufficiency are not significantly different from control levels.

Torremans A, Marescau B, Vanholder R, De Smet R, Billiouw JM, De Deyn PP.

Amino Acids. 2003 Jun;24(4):375-81.

PMID:
12768499
18.

Relationship between nonphenacetin-combined analgesics and nephropathy.

Lornoy W, Becaus I, Billiouw JM, Sierens L.

Kidney Int. 2001 Jun;59(6):2371-2; author reply 2372-3. No abstract available.

19.
20.

Images in clinical medicine. Xanthogranulomatous pyelonephritis.

Van Vlem B, Billiouw JM.

N Engl J Med. 2000 May 25;342(21):1572. No abstract available.

Supplemental Content

Loading ...
Support Center